| 7.79 0.34 (4.56%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 9.24 |
1-year : | 10.79 |
| Resists | First : | 7.91 |
Second : | 9.24 |
| Pivot price | 7.09 |
|||
| Supports | First : | 6.93 |
Second : | 6.32 |
| MAs | MA(5) : | 7.21 |
MA(20) : | 7.15 |
| MA(100) : | 5.45 |
MA(250) : | 4.48 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 79 |
D(3) : | 62.9 |
| RSI | RSI(14): 67.1 |
|||
| 52-week | High : | 7.91 | Low : | 1.9 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TKNO ] has closed Bollinger Bands are 25.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.92 - 7.94 | 7.94 - 7.97 |
| Low: | 7.24 - 7.26 | 7.26 - 7.29 |
| Close: | 7.74 - 7.78 | 7.78 - 7.83 |
Alpha Teknova, Inc. supplies vital scientific reagents to the life sciences sector across both the United States and international markets. These crucial materials play a key role in facilitating the exploration, evolution, and ultimate production of biopharmaceutical goods, such as advanced drug treatments, new vaccines, and molecular diagnostic solutions. The company's product offerings encompass pre-filled media plates designed for cell growth and replication; liquid cell culture media and complementary supplements that promote cellular proliferation; and various molecular biology reagents used for the handling, rehydration, and purification of samples. Teknova caters to a diverse clientele within the life sciences arena, including pharmaceutical companies, biotechnology firms, contract development and manufacturing organizations (CDMOs), in vitro diagnostic businesses, and academic and governmental research facilities. Founded in 1996, Alpha Teknova's main office is situated in Hollister, California.
Wed, 16 Sep 2026
Alpha Teknova Introduces Fill-Tek Dispensing System to Expand Custom Single-Use Bag Reagent Manufacturing - Quiver Quantitative
Mon, 24 Aug 2026
TKNO | Alpha Teknova, Inc. Common Financials - Revenue Breakdown - Quiver Quantitative
Mon, 24 Aug 2026
Alpha Teknova: Ample Manufacturing Capacity At A High Premium (NASDAQ:TKNO) - Seeking Alpha
Wed, 19 Aug 2026
Alpha Teknova Raises Outlook After Record Q2 Revenue at Sidoti Conference - Yahoo Finance
Wed, 19 Aug 2026
Alpha Teknova (TKNO) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 54 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 9.3 (%) |
| Held by Institutions | 87.3 (%) |
| Shares Short | 1,590 (K) |
| Shares Short P.Month | 1,580 (K) |
| EPS | -0.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.16 |
| Profit Margin | -38.4 % |
| Operating Margin | -23.8 % |
| Return on Assets (ttm) | -9.3 % |
| Return on Equity (ttm) | -24.2 % |
| Qtrly Rev. Growth | 18.5 % |
| Gross Profit (p.s.) | 0.28 |
| Sales Per Share | 0.81 |
| EBITDA (p.s.) | -0.17 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -25.13 |
| PEG Ratio | 0 |
| Price to Book value | 6.65 |
| Price to Sales | 9.57 |
| Price to Cash Flow | -66.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|